IQVIA™ Real-World Insights Bibliography

High?Expenditure Disease in the EU?28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?
Author(s): Wolfgang Greiner, Keyur Patel, Christina-Jane Crossman-Barnes, Troels Vingtoft Rye-Andersen, Christian Hvid, Tom Vandebrouck
Affiliations(s): Department for Health Economics, Bielefeld University, Bielefeld, Germany; IQVIA Ltd, HEOR, London, UK; Novo Nordisk Region Europe Pharmaceuticals A/S, Copenhagen, Denmark; Novo Nordisk Region Europe Pharmaceuticals A/S, Brussels, Belgium
Publication(s):  PharmacoEconomics-Open. 2021 Jan; doi.org/10.1007/s41669-020-00253-4
Document Type(s): Article,
Countries: Europe,
Click here for the abstract
C:
Y:
Diabetes, Health economics, Oncology,
2021
  L:
A:
English
Burden of illness, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Literature Review, Quality of life, Retrospective database analysis, Review,
  Add to report
 
 
Concerns, quality of life, access to care and productivity of the general population during the first 8 weeks of the coronavirus lockdown in Belgium and the Netherlands
Author(s): Hanne van Ballegooijen 1, Lucas Goossens 2, Ralph H Bruin 3, Renée Michels 3, Marieke Krol 3
Affiliations(s): 1IQVIA, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands. hanne.vanballegooijen@iqvia.com. 2Erasmus University Rotterdam, Erasmus School of Health Policy & Management, Rotterdam, The Netherlands. 3IQVIA, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands.
Publication(s):  1 IQVIA, Herikerbergweg 314, 1101 CT Amsterdam, The Netherlands. 2 Erasmus University Rotterdam, Erasmus School of Health Policy & Management, Rotterdam, The Netherlands
BMC Health Services Research (2021) 21:227
PMID: 33712010 PMCID: PMC7953179 DOI: 10.1186/s12913-021-06240-7
Document Type(s): Article,
Countries: Netherlands ,
Click here for the abstract
C:
Y:
Health economics, Health status & patient reported outcomes, Immunology and Vaccination,
2021
  L:
A:
English
Observational study, Patient questionnaire, Population Based Study, Public Health, Quality of life, Survey research,
  Add to report
 
 
The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
Author(s): Lars Holger Ehlers 1, Mark Lamotte 2, Sofia Monteiro 3, Susanne Sandgaard 4, Pia Holmgaard 4, Evan C Frary 4, Niels Ejskjaer 5 6 7
Affiliations(s): 1Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 2IQVIA Real World Solutions, Zaventem, Belgium. 3IQVIA Real World Solutions, London, UK. 4Boehringer Ingelheim Danmark A/S, København Ø, Hovedstaden, Denmark. 5Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. n.ejskjaer@rn.dk. 6Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark. n.ejskjaer@rn.dk. 7Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark. n.ejskjaer@rn.dk.
Publication(s):  Diabetes Therapy https://doi.org/10.1007/s13300-021-01040-y
IQVIA HEOR Zaventem Brussels
PMID: 33856655 PMCID: PMC8099952 DOI: 10.1007/s13300-021-01040-y
Document Type(s): 
Countries: Denmark,
Click here for the abstract
C:
Y:
Diabetes, Health economics,
2021
  L:
A:
English
Clinical setting: Primary care, Cost effectiveness,
  Add to report
 
 
Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Portugal
Author(s): Nuno Marques 1, Laetitia Gerlier 2, Mafalda Ramos 3, Helder Pereira 4, Sérgia Rocha 5, Ana Catarina Fonseca 6, Ana André 7, Ricardo Melo 8, Eduard Sidelnikov 9
Affiliations(s): 1Department of Cardiology, Centro Hospitalar e Universitário do Algarve, Faro, Portugal. 2IQVIA, Zaventem, Belgium. 3IQVIA, Zaventem, Belgium. Electronic address: mafalda.ramos@iqvia.com. 4Department of Cardiology, Hospital Garcia de Orta, Almada, Portugal. 5Department of Cardiology, Hospital de Braga, Braga, Portugal. 6Department of Neurology, Hospital de Santa Maria, Universidade de Lisboa, Lisboa, Portugal. 7Department of Neurology, Centro Hospitalar e Universitário do Algarve, Faro, Portugal. 8Amgen SA, Portugal. 9Amgen (Europe) GmbH, Rotkreuz, Switzerland.
Publication(s):  PMID: 33581948 DOI: 10.1016/j.repc.2020.05.019 IQVIA HEOR Zaventem Brussels
Revista Portuguesa de Cardiologia Volume 40, Issue 2, February 2021, Pages 109-115.
Document Type(s): Article,
Countries: Portugal,
Click here for the abstract
C:
Y:
Cardiovascular disease, Health economics,
2021
  L:
A:
English
Burden of illness, Clinical setting: Primary care, Prospective study,
  Add to report
 
 
Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China
Author(s): Ahmed Salem 1, Peng Men 2 3, Mafalda Ramos 4, Yan-Jun Zhang 5, Anastasia Ustyugova 6, Mark Lamotte 7
Affiliations(s): 1IQVIA, Real World Solutions, Zaventem 1930, Belgium. 2Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China. 3Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China. 4IQVIA, Global HEOR, Porto Salvo 2740-266, Portugal. 5Boehringer Ingelheim, Health Economics & Outcomes Research, Government Affairs & Market Access, Shanghai 200040, China. 6Boehringer Ingelheim, CardioMetabolism Respiratory, Ingelheim am Rhein 55216, Germany. 7IQVIA, Global HEOR, Zaventem 1930, Belgium.
Publication(s):  Journal of Comparative Effectiveness Research 2021 https://doi.org/10.2217/cer-2020-0284.
PMID: 33576249 DOI: 10.2217/cer-2020-0284
Document Type(s): Article,
Countries: China,
Click here for the abstract
C:
Y:
Diabetes, Health economics,
2021
  L:
A:
English
Clinical setting: Primary care, Cost effectiveness,
  Add to report
 
 
Potential clinical and economic impact of optimised maintenance therapy on discharged patients with COPD after hospitalisation for an exacerbation in China
Author(s): Ahmed Salem # 1, Heng Zhong # 2, Mafalda Ramos 1, Mark Lamotte 1, Hao Hu 3
Affiliations(s): 1Real World Evidence, IQVIA, Zaventem, Belgium. 2R&D China, AstraZeneca R&D, Shanghai, China. 3Institute of Chinese Medical Sciences, University of Macau, Macau, China haohu@um.edu.mo. #Contributed equally.
Publication(s):  BMJ Open 2021;11:e043664. doi:10.1136/bmjopen-2020-043664
e043664. doi:10.1136/bmjopen-2020-043664
PMID: 33910947 PMCID: PMC8094343 DOI: 10.1136/bmjopen-2020-043664
Document Type(s): Article,
Countries: Belgium, China,
Click here for the abstract
C:
Y:
Health economics, Respiratory disease,
2021
  L:
A:
English
Clinical setting: Primary care, Cost effectiveness,
  Add to report
 
 
A novel decision model to predict the impact of weight management interventions: The Core Obesity Model.
Author(s): Sandra Lopes 1, Henrik H Meincke 1, Mark Lamotte 2, Anamaria-Vera Olivieri 3, Michael E J Lean 4
Affiliations(s): 1Novo Nordisk A/S Søborg Denmark. 2IQVIA Zaventem Belgium. 3IQVIA Basel Switzerland. 4Human Nutrition School of Medicine, Dentistry and Nursing Royal Infirmary University of Glasgow Glasgow UK.
Publication(s):  Obesity Science & Practice 2021. https://doi.org/10.1002/osp4.495
Document Type(s): Article,
Countries: Belgium, Switzerland,
Click here for the abstract
C:
Y:
Health economics, Obesity,
2021
  L:
A:
English
Clinical setting: Primary care, Cost effectiveness,
  Add to report
 
 
Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy
Author(s): Colombo GL, Heiman F, Peduto I
Affiliations(s): Colombo GL: CEFAT - Department of Drug Sciences, University of Pavia, Pavia, Italy. Peduto I, Heiman F: IQVIA Solutions Italy S.r.l., Milan, Italy,
Publication(s):  Ther Clin Risk Manag. 2021 Apr 21;17:345-356. doi: 10.2147/TCRM.S301005
Document Type(s): Article,
Countries: Italy,
Click here for the abstract
C:
Y:
Health economics, Overactive bladder,
2021
  L:
A:
English
Clinical setting: Primary care, Cost of illness,
  Add to report
 
 
Cost-effectiveness and budget impact analysis of a patient visit support system for blindness reduction in Japanese patients with glaucoma
Author(s): Masakazu Yamada 1 , Tadashi Nakano 2 , Hiroyuki Matsuda 3 , Seok-Won Kim 3 , Yasutaka Takagi 4
Affiliations(s): 1Department of Ophthalmology, Kyorin University School of Medicine, Mitaka, Japan. 2Department of Ophthalmology, The Jikei University School of Medicine, Tokyo, Japan. 3Real World Evidence Solutions, IQVIA solutions Japan, Tokyo, Japan. 4Japan Medical Affairs Group, Santen Pharmaceutical Co., Ltd. Osaka, Japan.
Publication(s):  Journal medical economics
Document Type(s): Article,
Countries: Japan,
Click here for the abstract
C:
Y:
Health economics,
2020
  L:
A:
English
Budget impact, Cost effectiveness,
  Add to report
 
 
Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling
Author(s): Akihito Uda, MPH,* Yuki Eto, MSc,* Yuxin Li, MSc,† Hiroyuki Matsuda, MSc,‡ Sven Demiya, PhD, MBA,‡ Tomoyuki Watanabe, PhD,* Mihoko Ota, MMA,* Ryuichi Iwakiri, MD, PhD,* and Ataru Igarashi, PhD,§,‖
Affiliations(s):  *Japan Medical Office, Takeda Pharmaceutical Co. Ltd., Tokyo, Japan; †IQVIA Solutions UK Ltd., London, UK; ‡IQVIA Solutions Japan KK, Tokyo, Japan; §Unit of Public Health and Preventive Medicine, School of Medicine, Yokohama City University, Yokohama, Kanagawa, Japan; ‖Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo, Tokyo, Japan
Publication(s):  Crohn's & Colitis 360
Document Type(s): Article,
Countries: Japan,
Click here for the abstract
C:
Y:
Health economics,
2020
  L:
A:
English
Budget impact, Cost effectiveness, Economic evaluation,
  Add to report
 
 
 1 of 22 Next Page Last Page